eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 113 blog entries.
13 08, 2018

Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia

2018-08-13T16:53:51+00:00

Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia PALO ALTO, Calif., August 13, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 PREVENT study.  [...]

Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia2018-08-13T16:53:51+00:00
10 08, 2018

Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results

2018-08-10T13:36:31+00:00

Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results  PALO ALTO, Calif., August 10, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three and six months ended June 30, 2018 and provided a business update. Key Achievements 2Q 2018 To [...]

Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results2018-08-10T13:36:31+00:00
6 08, 2018

Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health

2018-08-06T16:55:38+00:00

Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health PALO ALTO, Calif., August 6, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today first patient enrolled in the [...]

Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health2018-08-06T16:55:38+00:00
31 07, 2018

Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection

2018-07-31T12:17:12+00:00

Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection PALO ALTO, Calif., July 31, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that it has received the [...]

Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection2018-07-31T12:17:12+00:00
4 06, 2018

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™

2018-06-04T15:46:20+00:00

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™ PALO ALTO, Calif., June 4, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that an oral presentation [...]

Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™2018-06-04T15:46:20+00:00
30 05, 2018

Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference

2018-05-30T22:08:39+00:00

Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference PALO ALTO, Calif. – May 30, 2018 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that David Cory, President and CEO, will present a corporate update at Jefferies 2018 Global Healthcare Conference [...]

Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference2018-05-30T22:08:39+00:00
24 05, 2018

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock

2018-05-24T15:10:29+00:00

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PALO ALTO, Calif., May 24, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today the pricing of its previously announced underwritten public offering.  The Company announced that [...]

Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock2018-05-24T15:10:29+00:00
23 05, 2018

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock

2018-05-23T22:01:56+00:00

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PALO ALTO, Calif., May 23, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a clinical-stage biopharmaceutical company focused on bringing to market novel product candidates for the treatment of rare diseases, announced today that it has commenced an underwritten public offering of its common stock.  Eiger intends [...]

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock2018-05-23T22:01:56+00:00
16 05, 2018

Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)

2018-05-16T12:06:33+00:00

Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF) Plans to Seek FDA Guidance for Potential Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) Indication PALO ALTO, Calif., May 16, 2018 – Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies [...]

Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)2018-05-16T12:06:33+00:00
11 05, 2018

Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results

2018-05-11T14:25:02+00:00

Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results Hepatitis Delta Virus (HDV) Program Moving into Phase 3 Phase 2 Clinical Results Planned Across All Pipeline Programs in Second Half 2018 Existing Cash Runway Extends Through Mid-2019 PALO ALTO, Calif., May 11, 2018 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of [...]

Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results2018-05-11T14:25:02+00:00